CD274 and esophageal squamous cell carcinoma: Pembrolizumab in combination with platinum‐ and fluoropyrimidine‐based chemotherapy is approved for the first‐line treatment of patients with locally advanced or metastatic ESCC in the United States and in Europe, in adults whose tumors express PD‐L1 (combined positive score ≥10).17, 18